BTK and B-cell chronic lymphocytic leukemia: The TIGIT pathway has also been studied in CLL [48], and its expression was inversely correlated with time to first treatment and the B cell receptor (BCR) signaling capacity, as determined by BTK activity and cell proliferation [48].